Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

129 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Diagnosis and treatment of acromegaly.
Katznelson L. Katznelson L. Growth Horm IGF Res. 2005 Jul;15 Suppl A:S31-5. doi: 10.1016/j.ghir.2005.06.007. Growth Horm IGF Res. 2005. PMID: 16023876 Review.
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Swearingen B, et al. J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26. doi: 10.1210/jcem.83.10.5222. J Clin Endocrinol Metab. 1998. PMID: 9768641
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Trainer PJ, et al. N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604. N Engl J Med. 2000. PMID: 10770982 Clinical Trial.
Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study.
Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A. Katznelson L, et al. Clin Endocrinol (Oxf). 2001 Feb;54(2):183-8. doi: 10.1046/j.1365-2265.2001.01214.x. Clin Endocrinol (Oxf). 2001. PMID: 11207632 Clinical Trial.
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. van der Lely AJ, et al. Lancet. 2001 Nov 24;358(9295):1754-9. doi: 10.1016/s0140-6736(01)06844-1. Lancet. 2001. PMID: 11734231 Clinical Trial.
FINDINGS: Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 mg/L (2.1), 12.5 mg/L
FINDINGS: Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in p …
Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A. Sesmilo G, et al. J Clin Endocrinol Metab. 2002 Apr;87(4):1692-9. doi: 10.1210/jcem.87.4.8364. J Clin Endocrinol Metab. 2002. PMID: 11932303 Clinical Trial.
Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A. Fairfield WP, et al. Clin Endocrinol (Oxf). 2002 Sep;57(3):385-90. doi: 10.1046/j.1365-2265.2002.01624.x. Clin Endocrinol (Oxf). 2002. PMID: 12201832 Clinical Trial.
During the 12-week placebo-controlled period, there were significant decreases in serum markers of bone formation, osteocalcin (-2.2 +/- 0.44 vs. placebo +0.01 +/- 0.39 nmol/l, P = 0.009) and PICP (-23.6 +/- 9.6 vs. placebo +18.1 +/- 12.8 micro g/l, P = 0.022) and a …
During the 12-week placebo-controlled period, there were significant decreases in serum markers of bone formation, osteocalcin (-2.2 +/- 0.4 …
Effects of growth hormone secretion on body composition in patients with Crohn's disease.
Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, Klibanski A. Katznelson L, et al. J Clin Endocrinol Metab. 2003 Nov;88(11):5468-72. doi: 10.1210/jc.2003-030608. J Clin Endocrinol Metab. 2003. PMID: 14602791
AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.
Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML; AACE Acromegaly Guidelines Task Force. Cook DM, et al. Endocr Pract. 2004 May-Jun;10(3):213-25. doi: 10.4158/EP.10.3.213. Endocr Pract. 2004. PMID: 15382339 No abstract available.
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Freda PU, et al. J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73. doi: 10.1210/jc.2005-0260. Epub 2005 May 10. J Clin Endocrinol Metab. 2005. PMID: 15886238
129 results
Jump to page
Feedback